Skip to main content Back to Top

Best Practice in Formulary Management: Biosimilar Reimbursement Challenges


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Joel Hennenfent, Pharm.D., M.B.A., BCPS, FASHP, sits down with Ali McBride, Pharm.D., M.S., BCPS, to discuss biosimilar formulary implementation/integration and reimbursement challenges.

To learn more about Formulary Management Strategies visit


Ali McBrideAli McBride, Pharm.D., M.S., BCPS, BCOP,  is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center.  He currently serves as Secretary of the Association of Community Cancer Centers (ACCC) and he has been actively involved with the American Society of Health-System Pharmacists (ASHP) currently serving as the Chair for the Section Advisory Group on Emerging Sciences in the Section of Clinical Specialists and Scientists.

Dr. McBride has been working on oncology drug shortages and has testified on behalf of Hematology/Oncology Pharmacy Association (HOPA) at the FDA Drug Shortage Workshop, presented on behalf of the Association of Community Cancer Centers (ACCC) at the Washington D.C. Congressional Session and was an invited member of the ASHP Drug Shortage Stakeholders Meeting.  Dr. McBride is also actively involved with biosimilar regulation and the pharmacogenomic impact of biosimilars into the United States marketplace.  He currently serves as a working group member for HOPA on its biosimilar committee.  In addition, he currently serves on the National Quality Forum (NQF) Cancer Standing Committee.   He has published numerous articles focusing on drug shortages, oral chemotherapy adherence, stem cell transplant, and biosimilar implementation into the U.S. health care market. 

Joel HennenfentJoel A. Hennenfent, Pharm.D., M.B.A., BCPS, FASHP, is the Chief Pharmacy Officer & Associate Administrator for Laboratory and Medical Imaging Services at Truman Medical Centers in Kansas City, Missouri. He earned his Bachelor of Science and Doctor of Pharmacy degrees at St. Louis College of Pharmacy, completed a Pharmacy Practice Residency at Barnes-Jewish Hospital, and a Master’s degree in Business Administration from Saint Louis University.  Joel is a Past President of Missouri Society of Health-System Pharmacists (MSHP), Past President of St. Louis Society of Health-System Pharmacists (STLSHP), and Past Chair of MSHP Research & Education Board. Moreover, he was the 2013 ASHP Council on Therapeutics Chair, 2015-2017 ASHP Section of Clinical Specialists and Scientists Executive Committee Director-at-Large, a 2014-2018 and 2015-2019 ASHP Foundation Pharmacy Forecast Advisory Committee member, the 2012 MSHP Pharmacist of the Year, and 2015 MSHP Foundation Garrison Award Recipient. Joel is currently serving as ASHP Delegate for Missouri, member of ASHP Pharmacy Executive Leadership Alliance (PELA) Advisory Panel, ASHP Formulary Submission Toolkit Steering Committee, Editor for the ASHP Pharmacy Competency Assessment Center (PCAC) and Board Member of the St. Louis College of Pharmacy Board of Trustees.

This podcast is provided by ASHP and sponsored by Merck.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.